Search the Newsreel

Vertex to acquire Crinetics after HSR clearance; closing expected early Sept

Crinetics Pharmaceuticals announced that it has received HSR clearance for its merger with Vertex. The HSR waiting period expired on August 12, 2026, and antitrust approvals have also been secured in Austria, Germany, and Australia. The merger's closing is targeted for early September 2026, …

Crinetics Pharmaceuticals (CRNX): Wellington reports 7.13M-share, 6.76% ownership

Wellington Management entities have reported beneficial ownership of 7,131,084 shares, or 6.76%, of Crinetics Pharmaceuticals (CRNX) common stock. The filing indicates shared voting power over 6,310,651 shares and shared dispositive power over all 7,131,084 shares, with economic interests belonging to advisory clients. No single …

Crinetics Pharmaceuticals stock hits all-time high at 84.35 USD

Crinetics Pharmaceuticals (CRNX) stock reached an all-time high of $84.35, reflecting a 196.14% increase over the past year and a current market capitalization of approximately $8.94 billion. Despite its strong performance, InvestingPro data suggests the stock might be overbought and overvalued. The company recently …

First Trust Advisors LP Raises Stake in Crinetics Pharmaceuticals, Inc. $CRNX

First Trust Advisors LP increased its stake in Crinetics Pharmaceuticals (CRNX) by 54.9% in the first quarter, now holding 51,365 shares valued at $1.87 million. Despite insider stock sales, the company reported strong Q1 earnings, beating revenue estimates by 2336.9% year-over-year. Analysts have a …

Crinetics Pharmaceuticals Inc (CRNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Crinetics Pharmaceuticals (NASDAQ: CRNX) sees 1.4% stake reported by FMR LLC

FMR LLC and Abigail P. Johnson have reported an amended passive investment disclosure for Crinetics Pharmaceuticals (CRNX) via a Schedule 13G/A filing. FMR LLC holds beneficial ownership of 1,439,890.88 shares, representing 1.4% of the common stock outstanding, with nearly all shares holding sole voting …

Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by Glenmede Trust Co. NA

Glenmede Trust Co. NA increased its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) by 72.6% in the first quarter, now holding 29,245 shares valued at $1.06 million. Despite some insider selling, institutional investors own 98.51% of the company. Crinetics Pharmaceuticals reported better-than-expected Q1 earnings with a …

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Vertex Pharmaceuticals (NASDAQ: VRTX) has dominated the market for cystic fibrosis (CF) medicines since it earned approval for its first drug in this niche in 2012. To this day, most of the company's revenue comes from its CF franchise. In the second quarter, Vertex …

Crinetics Pharmaceuticals (CRNX) Stock Looks Rich On Book Value But Reasonable On Deal Value

Crinetics Pharmaceuticals (CRNX) has experienced a significant stock price increase of 403.6% over three years, making its current valuation appear high on market multiples. While the agreed acquisition by Vertex Pharmaceuticals for US$10.0 billion helps justify the current price, the stock's Price-to-Book ratio of …

Crinetics Pharmaceuticals (CRNX) Stock Lags As Revenue Builds And Losses Deepen

Crinetics Pharmaceuticals (CRNX) has shown significant revenue growth, with Q2 2026 revenue reaching US$25.1 million, largely due to scaling product sales like PALSONIFY. Despite this, the company's net losses have deepened, reporting a US$120.9 million quarterly loss and a US$501.6 million trailing 12-month loss. …

Crinetics Pharmaceuticals stock hits all-time high at 84.01 USD

Crinetics Pharmaceuticals' stock has reached an all-time high of $84.01, driven by a 187.21% increase over the past year and a market capitalization of $8.85 billion. This surge in value comes as Vertex Pharmaceuticals announced an agreement to acquire Crinetics for approximately $10 billion, …

Crinetics Pharmaceuticals (CRNX) On Vertex Deal Optimism And Results Looks Nearly Fully Valued

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Crinetics Pharmaceuticals (CRNX) is in focus after reporting second quarter 2026 results that paired …

Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says

Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week High After Better-Than-Expected Earnings

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.73 per share for the second quarter of 2026, missing the Zacks Consensus Estimate of $4.79. Earnings, however, rose around 4.6% year over year on higher product revenues. Second-quarter total revenues of $3.33 billion beat the Zacks …

Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary - Moby Strategic Execution and Portfolio Expansion Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to …

Crinetics Reports Wider Q2 Loss; Withdraws Guidance Ahead Of Company's Acquisition

(RTTNews) - Crinetics Pharmaceuticals, Inc. (CRNX) reported a wider net loss for the second quarter ended June 30, 2026, and also provided various business highlights. The company recently began generating revenue with the commercial launch of PALSONIFY (Paltusotine) for acromegaly. Company Profile Crinetics Pharmaceuticals …

Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price …

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: Revenue Growth Surges by 2,873% Amidst Strong Biotech Potential

Is Crinetics Pharmaceuticals (CRNX) Undervalued After Q2 Earnings Miss? GF Score: 47/100, Revenue at $25.1M

Crinetics (Nasdaq: CRNX) agrees to $85 cash-per-share sale to Vertex

Crinetics Pharmaceuticals announced it has agreed to be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, totaling approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. The acquisition is expected to close in the third quarter of 2026, pending regulatory …

Crinetics Pharmaceuticals GAAP EPS of -$1.14 beats by $0.07, revenue of $25.12M beats by $10.25M

* Crinetics Pharmaceuticals press release [https://seekingalpha.com/pr/20604770-crinetics-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-business] (CRNX [https://seekingalpha.com/symbol/CRNX]): Q2 GAAP EPS of -$1.14 beats by $0.07. * Revenue of $25.12M (+2412.0% Y/Y) beats by $10.25M. * Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net …

Earnings Flash (CRNX) Crinetics Pharmaceuticals, Inc. Reports Q2 Revenue $25.1M, vs. FactSet Est of $14.8M

Crinetics Pharmaceuticals, Inc. (CRNX) announced its Q2 revenue of $25.1 million, significantly exceeding the FactSet estimate of $14.8 million. The company is a clinical-stage pharmaceutical firm specializing in treatments for rare endocrine diseases and endocrine-related tumors, with lead candidates PALSONIFY and Atumelnant. This strong …

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals, Inc. Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026 SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- …

Trading Systems Reacting to (CRNX) Volatility

This article analyzes Crinetics Pharmaceuticals Inc. (CRNX) using AI models to provide trading strategies. It notes a neutral near and mid-term outlook but a positive long-term bias, with no resistance levels above the current price suggesting upside potential. The report details position trading, momentum …

Farallon discloses 8.5% Crinetics stake in Schedule 13G/A (CRNX)

Farallon Capital Management, L.L.C. has disclosed an 8.5% beneficial ownership stake in Crinetics Pharmaceuticals, Inc. (CRNX) through a Schedule 13G/A filing. As of June 30, 2026, Farallon holds 8,989,098 shares of Crinetics' common stock across several investment partnerships, with senior members Joshua J. Dapice …

Crinetics Pharmaceuticals (NASDAQ:CRNX) Issues Earnings Results

Crinetics Pharmaceuticals (CRNX) Earnings Date and Reports 2026

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.23 per share a year ago. These figures are adjusted for non-recurring items. This …

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

This has been an active year in the mergers-and-acquisitions landscape across the biopharmaceutical industry. One of the more notable deals was Vertex Pharmaceuticals' acquisition of Crinetics Pharmaceuticals for $10 billion in cash (the transaction hasn't closed yet). This is the largest acquisition in Vertex …

Crinetics Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Crinetics Pharmaceuticals (CRNX) has approximately 611 employees worldwide as of March 2026, marking a 114.5% growth from 285 employees in 2023. The company, headquartered in San Diego, California, is actively hiring with 163 job postings in 2026. Its workforce is primarily concentrated in the …

Crinetics Pharmaceuticals Inc (CRNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Crinetics Pharmaceuticals Inc (CRNX), detailing its current price momentum score, support and resistance levels, and various technical indicators. It outlines buy, neutral, and sell signals based on MACD, RSI, KDJ, and moving averages, concluding with a "Neutral" …